CRYL1 and glioblastoma: We thus investigated the effects of pharmacological modulation of the circadian clock in terms of cell viability, proliferation, and migration on GBM cultures using the CK1ε/δ inhibitor (PF670462), the GSK-3 inhibitor (CHIR99021), and the CRY protein stabilizer (KL001).